Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: CA Cancer J Clin. 2013 Jul 15;63(5):318–348. doi: 10.3322/caac.21190

Table 4.

Genetic Alterations in Common Neoplasms of the Pancreas

Tumor type Gene(s) Prevalence of the
Alteration
Comment
Acinar cell carcinoma APC 15%
CTNNB1 (beta-catenin) 5%
Invasive ductal adenocarcinoma KRAS 95%
p16/CDKN2A 95%
TP53 75%
SMAD4 55% SMAD4 loss associated with poor prognosis and widespread disease
MLL3, TGFBR2, FBXW7, ARID1A,AIRID2, and ATM <5% Some of these, such as ATM, may be targetable therapeutically
IPMN KRAS 80%
RNF43 75% RNF43 is a marker of mucin-producing tumors as it is present in both IPMNs and MCNs
GNAS 60% GNAS is a marker of IPMNs. GNAS and/or KRAS mutations are present in >95% of all IPMNs
p16/CDKN2A Varies dependent on histologic grade
TP53 Varies dependent on histologic grade Associated with higher grade lesions
SMAD4 Varies dependent on histologic grade Associated with higher grade lesions
PIK3CA 10%
MCN KRAS 75%
RNF43 40% RNF43 is a marker of mucin-producing tumors--IPMNs and MCNs
p16/CDKN2A Varies dependent on histologic grade
TP53 Varies dependent on histologic grade Associated with higher grade lesions
SMAD4 Varies dependent on histologic grade Associated with higher grade lesions
Pancreatoblastoma Imprinted region on chromosome 11 85% Same region is targeted in hepatoblastoma and Wilms tumors
CTNNB1 (beta-catenin) 55%
APC 10%
PanNET MEN1 45%
DAXX or ATRX 45%
TSC2, PTEN, DDIT4, and PIK3CA (mTOR Pathway genes) 15% Potentially targetable therapeutically with everolimus
SCN VHL 50% Among the cystic tumors of the pancreas, VHL loss is specific for SCN
SPN CTNNB1 (beta-catenin) 95% Immunolabeling for beta-catenin is useful diagnostically

IPMN=intraductal papillary mucinous neoplasm; MCN=mucinous cystic neoplasm; PanNET=pancreatic neuroendocrine tumor; SCN=serous cystic neoplasm; SPN=solid-pseudopapillary neoplasm